Zelboraf, which targets the mutated BRAF gene, is used to treat melanoma, but it isn’t always successful due to melanoma’s ability to sometimes get around the inhibitor. Now, scientists have a better idea of the mechanism behind the melanoma resistance. By examining the exome, researchers found that the mutated BRAF gene driving the cancer becomes amplified by the drug, essentially outnumbering the inhibitor.
Cancer is tough to kill and has many ways of evading the drugs used by oncologists to eliminate it.
Now, researchers at UCLA’s Jonsson Comprehensive Cancer Center have uncovered how an advanced form of melanoma gets around an inhibitor called Zelboraf, which targets the mutated BRAF gene.
By examining the part of the melanoma genome that encodes proteins, called the exome, Jonsson Cancer Center scientists discovered that in some patients with BRAF-mutated metastatic melanoma, the mutated BRAF gene driving the cancer becomes amplified as the cancer develops resistance to an inhibitor.
Quite simply, by increasing the copies of the mutated BRAF gene, the melanoma is trying to over-produce the protein targeted by the drug, essentially outnumbering the inhibitor. The study findings may lead to alternative ways of preventing or treating resistant melanomas.
“Understanding and solving the problem of how cancer gets around targeted drugs is arguably one of the highest priorities in modern-day cancer medicine,” said the study’s senior author Dr. Roger Lo, an assistant professor of dermatology and of molecular and medical pharmacology and a Jonsson Cancer Center scientist. “In this study, we found that in some patients, the cancer simply makes more of the target, the mutated BRAF gene, so that the drug dose becomes too weak to fight the cancer.
“If you think of the mutation as a right hand and the BRAF inhibitor as a left hand and the two clasp to be effective, there’s clearly an optimal ratio to ensure the mutated gene is fully inhibited. Here, we get more of the drug target, which has the same effect as dropping the drug level.”
The one-year study is published March 6 in the peer-reviewed journal Nature Communications.
About 50 percent of patients with metastatic melanoma, roughly 4,000 people a year, have the BRAF mutation and can be treated with Zelboraf, two pills taken twice a day. Zelboraf was approved by the U.S. Food and Drug Administration for use in metastatic melanoma in August of 2011. Many other common human cancers, including cancers of the colon, thyroid and lung, also harbor BRAF-mutated subsets, Lo said.
Oncologists cannot give more Zelboraf to these patients to combat the increased number of mutated BRAF genes because the dose approved by the FDA is the maximum tolerated dose, Lo said. However, Zelboraf could perhaps be given with inhibitors of other cell-signaling pathways in metastatic melanoma to try to stop patients from becoming resistant.
Lo and his team examined samples from 20 patients for this study, taking their normal tissue, their tumor tissue before treatment with Zelboraf, and a tissue sample when the cancer had responded earlier but subsequently became resistant. Using high-throughput DNA sequencing technology, the scientists examined the entire cancer exome to see what changes were occurring that may point to resistant mechanisms.
Lo found that five of the 20 patients showed increased copies of the mutated BRAF gene. Cell lines developed from melanoma patients also showed pathways downstream of the amplified gene that could be blocked with inhibitors to fight resistance.
“For the first time, we were able to see in actual patient tissue samples how the cancer gets around this drug by altering the target,” Lo said. “It appears that the drug target is not only mutated and hyper-activated, but it’s also massively over-produced in some cases of clinical relapse.”
Lo said there’s an experimental drug that also inhibits mutated BRAF which may be effective against this form of melanoma at a dose that does not result in substantial side effects. In that case, an oncologist might have room to increase the drug dose once a relapse driven by BRAF amplification is encountered in the clinic.
Scientists so far have discovered five mechanisms of BRAF-inhibitor resistance in melanoma patients, accounting for about 60 to70 percent of patients. However, 30 to 40 percent of patients are relapsing by as-yet uncovered mechanisms.
Going forward, Lo and his team will seek to find out what is happening molecularly in every patient that relapses after therapy so that novel combination drug strategies can be developed to help them.
“If we know what happens in every relapse, we can have a plan in place that will help us avoid or overcome resistance,” he said.
About 70,000 new cases of melanoma are diagnosed each year in the United States. Of those, 8,000 people will die of the disease.
The study was funded by a Bud and Sue Selig Innovative Research Grant from Stand Up to Cancer, the Burroughs Wellcome Fund, the Seaver Institute, and the Richard C. Seaver Charitable Trust. Additional support came from the National Cancer Institute, the V Foundation for Cancer Research, the Melanoma Research Foundation, the Melanoma Research Alliance, the American Skin Association, the Caltech–UCLA Joint Center for Translational Medicine, the Sidney Kimmel Foundation for Cancer Research, Wendy and Ken Ruby, and Louis Belley and Richard Schnarr.
Image: UCLA Newsroom